Oramed Pharmaceuticals Inc. (ORMP) stock
ORMPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 12/30
$3.69−0.20 (-5.14%)
Close on Nov 19, 2026Market cap $153.49MP/E 0.9Yield 6.78%
Oramed Pharmaceuticals gross profit
Gross profit is revenue minus the direct cost of the goods and services sold.
Oramed Pharmaceuticals's gross profit for the twelve months ending Dec 31, 2025 was $13.00K. For fiscal 2025 it was $13.00K, down 99.5% from the year before. The highest annual figure on record is $2.61M in fiscal 2019.
Annual gross profit
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $13.00K | -99.5% |
| FY2019 | Aug 31, 2019 | $2.61M | +3.1% |
| FY2018 | Aug 31, 2018 | $2.54M | +11.7% |
| FY2017 | Aug 31, 2017 | $2.27M | +1402.6% |
| FY2016 | Aug 31, 2016 | $151.00K | – |
Quarterly gross profit
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2025CQ4 2025 | Dec 31, 2025 | $0 | -100.0% |
| Q3 FY2025CQ3 2025 | Sep 30, 2025 | $0 | -100.0% |
| Q2 FY2025CQ2 2025 | Jun 30, 2025 | $0 | -100.0% |
| Q1 FY2025CQ1 2025 | Mar 31, 2025 | $13.00K | -98.2% |
| Q4 FY2019CQ3 2019 | Aug 31, 2019 | $681.00K | +10.2% |
| Q3 FY2019CQ2 2019 | May 31, 2019 | $682.00K | +10.5% |
| Q4 FY2018CQ3 2018 | Aug 31, 2018 | $617.00K | +1.0% |
| Q3 FY2018CQ2 2018 | May 31, 2018 | $703.00K | +66.2% |
| Q4 FY2017CQ3 2017 | Aug 31, 2017 | $618.00K | +44.7% |
| Q3 FY2017CQ2 2017 | May 31, 2017 | $617.00K | – |
| Q2 FY2017CQ1 2017 | Feb 28, 2017 | $611.00K | +405.0% |
| Q1 FY2017CQ4 2016 | Nov 30, 2016 | $423.00K | – |
| Q4 FY2016CQ3 2016 | Aug 31, 2016 | $427.00K | – |
| Q3 FY2016CQ2 2016 | May 31, 2016 | -$155.00K | – |
| Q2 FY2016CQ1 2016 | Feb 29, 2016 | $121.00K | – |
See a number that looks wrong?